RussellRG, MuhlbauerRCS, BisazDet al.The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapetite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif Tissue Res, 1970; 6:183–189.
2.
RussellRGG, RogersM. Bisphosphonates: From the laboratory to the clinic and back again. Bone, 1999; 25:97–106.
3.
RogersM. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des, 2003; 9:2643–2658.
4.
NancollasGH, TangR, PhippsRJet al.Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapetite. Bone, 2006; 38:617–627.
5.
RussellRGG, WattsNB, EbetinoFH, RogersMJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, 2008; 19:733–759.
6.
MillerPD. Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. MarcusR, FeldmanD, NelsonDA, RosenCJ. Osteoporosis, 3rd. San Diego, CA: Elsevier Academic Press, 2007; 1725–1736.
7.
WasnichRD, MillerPD. Antifracture efficacy of antiresportive agents are related to changes in bone density. J Clin Endocrinol Metab, 2000; 85:1–6.
8.
BorahB, DufresneTE, ChmielewskiPAet al.Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res, 2002; 17:1139–1147.
9.
BorahB, DufresneTE, RitmanTLet al.Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone, 2006; 39:345–352.
10.
BaussF, DempsterDW. Effects of ibandronate on bone quality: Preclinical studies. Bone, 2007; 40:265–273.
11.
BilezikianJP, MatsumotoT, BellidoTet al.Targeting bone remodeling for the treatment of osteoporosis: Summary of the proceedings of an ASBMR workshop. J Bone Miner Res, 2009; 24:373–385.
12.
BonnickSL, SaagKG, KielDPet al.Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab, 2006; 91:2631–2637.
13.
MillerPD, EpsteinS, SedaratiF, ReginsterJY. Once monthly oral ibandronate compared with weekly alendronate: Results from the head-to-head MOTION study. Curr Med Res Opin, 2008; 24:207–213.
14.
WattsNB, GeusensP, BartonIP, FelsenbergD. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res, 2005; 20:2097–2104.
15.
SeemanE. Is a change in bone mineral density a sensitive and specific surrogate of antifracture efficacy?Bone, 2007; 41:308–317.
16.
RavnP, ThompsonDE, RossPD, ChristiansenC. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone, 2003; 33:150–158.
17.
CremersS, BilezikianJP, GarneroP. Bone markers—New aspects. Clin Lab, 2008; 54:461–471.
18.
EastellR, BartonI, HannonRA, ChinesA, GarneroP, DelmasPD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res, 2003; 18:1051–1056.
19.
ReginsterJY, ColletteJ, NeuprezA, ZegelsB, DeroisyR, BruyereO. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone, 2008; 42:832–836.
20.
BaimSR, MillerPD. The role of serum C-telopeptide (CTX) in the management of postmenopausal osteoporosis and its use in predicting osteonecrosis of the jaw (ONJ)J Bone Miner Res, 2009; 24:561–574.
21.
MillerPD, HochbergMC, WehrenLEet al.How useful are measures of BMD and bone turnover?Curr Med Res Opin, 2005; 21:545–554.
BonnickSL, ShulmanL. Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both?Am J Med, 2006; 119,Suppl 1:S25–31.
24.
BlackDM, DelmasPD, EastellRet al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 2007; 356:1809–1822.
25.
McClungMR, GeusensP, MillerPDet al.The effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 2001; 344:333–340.
26.
BlackDM, CummingsSR, KarpfDBet al.Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 1998; 348:1535–1541.
27.
Chesnut CHIII, SkagA, ChristiansenCet al.Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004; 19:1241–1249.
28.
HarrisST, BlumenthalsWA, MillerPD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin, 2008; 24:237–245.
29.
MillerPD. Non-vertebral fracture risk reduction with oral bisphosphonates: Challenges with interpreting clinical trial data. Curr Med Res Opin, 2008; 24:107–119.
30.
BoonenS, LaanRF, BartonIP, WattsNB. Effect of osteoporosis treatments on risk of non-vertebral fractures: Review and meta-analysis of intention-to-treat studies. Osteoporos Int, 2005; 16:1291–1298.
31.
LylesKW, Colon-EmericCS, MagazinerJSet al.Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med, 2007; 357:1799–1809.
32.
BoonenS, SellmeyerDE, LippunerKet al.Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int, 2008; 74:641–648.
33.
LewieckiEM, MillerPD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Safety, 2007; 6:663–672.
34.
MillerPD. Fragility fractures in chronic kidney disease: An opinion-based approach. Cleve Clin J Med, 2009; 76:715–723.
